SCHEMBL4724475

SCHEMBL4724475

CCOc1cn[c]c(-c2cccc3ccccc23)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 2/20 0.39
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
FDPS P14324 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723379 0.89 ALDH1A1 (0.40) L3MBTL1MEN1MAPTTSHRKMT2A
SCHEMBL4723492 0.88 HTR1B (0.41) L3MBTL1MAPTHPGDALDH1A1GAA
SCHEMBL4722641 0.84 KDM4E (0.39) L3MBTL1MEN1MAPTHPGDTSHR
SCHEMBL4720234 0.78 ALDH1A1 (0.44) MAPTHPGDTSHRALDH1A1GAA
SCHEMBL4724855 0.72 ENPP1 (0.44) ENPP1S1PR1S1PR3POLBL3MBTL1
SCHEMBL4722076 0.69 GSK3B (0.43) L3MBTL1MAPTHPGDTSHRALDH1A1
SCHEMBL27605514 0.69 S1PR1 (0.43) ENPP1S1PR1S1PR3POLBL3MBTL1
SCHEMBL4723129 0.69 ENPP1 (0.44) ENPP1S1PR1S1PR3POLBL3MBTL1
SCHEMBL4724523 0.69 S1PR1 (0.44) ENPP1S1PR1S1PR3POLBMEN1
SCHEMBL10823555 0.67 ENPP1 (0.57) ENPP1S1PR1S1PR3TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 ENPP1 414/4885S1PR1 618/4885S1PR3 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.